Table 4.
RFS (# events, 95% CI) | DMFS (# events, 95% CI) | MSS (# events, 95% CI) | |
---|---|---|---|
Class 1 (n = 159) | 79% (37, 72–85%) | 87% (24, 82–93%) | 97% (7, 94–100%) |
Class 2 (n = 178) | 51% (89, 44–59%) | 59% (74, 51–67%) | 78% (35, 71–85%) |
SLN- (n = 180) | 79% (43, 73–85%) | 85% (32, 80–91%) | 95% (9, 92–99%) |
SLN+ (n = 157) | 47% (82, 39–56%) | 55% (66, 47–65%) | 75% (33, 68–84%) |
Class 1/SLN- (n = 103) | 87% (15, 81–94%) | 93% (9, 88–98%) | 98% (2, 95–100%) |
Class 1/SLN+ (n = 56) | 61% (22, 49–76%) | 74% (15, 63–88%) | 93% (5, 86–100%) |
Class 2/SLN- (n = 77) | 67% (28, 57–79%) | 75% (23, 66–85%) | 92% (7, 85–98%) |
Class 2/SLN+ (n = 101) | 37% (60, 28–49%) | 44% (51, 34–56%) | 63% (28, 52–76%) |
CI confidence interval, DMFS distant metastasis-free survival, GEP gene expression profile, RFS recurrence-free survival, SLN sentinel lymph node, MSS melanoma-specific survival